9995
COM:REMEGEN
荣昌生物制药（烟台）股份有限公司
- Stock
Last Close
18.06
22/11 08:08
Market Cap
14.40B
Beta: -
Volume Today
2.35M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|
net income | -269.95M - | -430.28M 59.39% | -697.82M 62.18% | 276.26M 139.59% | -998.83M 461.56% | -1.51B 51.30% | |
depreciation and amortization | 22.64M - | 42.77M 88.93% | 77.67M 81.58% | 120.47M 55.12% | 186.37M 54.70% | 233.51M 25.29% | |
deferred income tax | 421K - | 13.49M 3,104.75% | 53.54M 296.81% | ||||
stock based compensation | 3.02M - | 5.13M 69.57% | 16.56M 223.12% | 19.22M 16.07% | 55.77M 190.11% | 85.56M 53.42% | |
change in working capital | 77.80M - | 55.55M 28.61% | -97.61M 275.73% | -168.16M 72.28% | -523.64M 211.39% | -579.37M 10.64% | |
accounts receivables | -39.31M - | -488.32M 1,142.25% | -344.61M 29.43% | ||||
inventory | -7.80M - | -1.58M 79.80% | -34.90M 2,114.40% | -214.04M 513.32% | -241.76M 12.95% | -234.76M 2.90% | |
accounts payables | 39.31M - | 488.32M 1,142.25% | |||||
other working capital | 85.60M - | 57.12M 33.27% | -62.71M 209.78% | 45.88M 173.17% | -281.88M 714.34% | ||
other non cash items | 38.46M - | 43.67M 13.56% | 27.63M 36.73% | -37.70M 236.44% | 16.64M 144.14% | 268.71M 1,514.84% | |
net cash provided by operating activities | -128.03M - | -282.75M 120.85% | -660.08M 133.45% | 263.63M 139.94% | -1.26B 579.34% | -1.50B 18.92% | |
investments in property plant and equipment | -83.72M - | -65.21M 22.11% | -480.83M 637.37% | -617.34M 28.39% | -757.52M 22.71% | -852.76M 12.57% | |
acquisitions net | 5M - | -37.26M - | -1.50M - | ||||
purchases of investments | -102M - | -1.90B - | |||||
sales maturities of investments | 102.29M - | 1.85B - | |||||
other investing activites | 1.55M - | -29.89M 2,028.45% | 38.74M 229.62% | -20.61M 153.19% | -25.22M 22.39% | 36.10M 243.12% | |
net cash used for investing activites | -77.17M - | -95.10M 23.23% | -479.06M 403.75% | -637.95M 33.17% | -841.56M 31.92% | -816.66M 2.96% | |
debt repayment | -86.79M - | -295.05M 239.97% | -1.18B 300.48% | -108M 90.86% | -45.28M 58.07% | -1.06B 2,238.52% | |
common stock issued | 3.77B - | -449.17M 111.91% | 2.57B 672.51% | ||||
common stock repurchased | -449.17M - | -40.92M 90.89% | -99.37M 142.83% | ||||
dividends paid | -449.17M - | -86.20M 80.81% | -15.41M 82.12% | ||||
other financing activites | 293.08M - | 702.37M 139.65% | 1.31B 87.03% | 828.61M 36.92% | 27.82M 96.64% | 34.21M 22.99% | |
net cash used provided by financing activities | 206.29M - | 407.32M 97.45% | 3.90B 858.51% | -626.90M 116.06% | 2.43B 487.14% | 978.31M 59.69% | |
effect of forex changes on cash | -31.11M - | -10.49M 66.29% | -9.34M 10.90% | -1.46M 84.40% | |||
net change in cash | 1.09M - | 29.48M 2,606.70% | 2.73B 9,175.26% | -1.01B 137.00% | 312.36M 130.87% | -1.34B 529.83% | |
cash at beginning of period | 3.98M - | 5.07M 27.36% | 34.55M 581.50% | 2.77B 7,914.25% | 1.76B 36.54% | 2.07B 17.78% | |
cash at end of period | 5.07M - | 34.55M 581.50% | 2.77B 7,914.25% | 1.76B 36.54% | 2.07B 17.78% | 726.55M 64.89% | |
operating cash flow | -128.03M - | -282.75M 120.85% | -660.08M 133.45% | 263.63M 139.94% | -1.26B 579.34% | -1.50B 18.92% | |
capital expenditure | -83.72M - | -65.21M 22.11% | -480.83M 637.37% | -617.34M 28.39% | -757.52M 22.71% | -852.76M 12.57% | |
free cash flow | -211.75M - | -347.95M 64.32% | -1.14B 227.89% | -353.71M 69.00% | -2.02B 471.43% | -2.36B 16.54% |
All numbers in (except ratios and percentages)